{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T17:18:09Z","timestamp":1763227089582,"version":"3.41.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ustekinumab is a recently introduced biological agent for the treatment of Crohn\u2019s disease. The clinical use of the trough concentration of ustekinumab is not as standardized as that of infliximab. The authors aimed to introduce a measurement method and the results of trough concentrations of ustekinumab in clinical applications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Thirty-two blood samples from 10 young adult patients diagnosed with Crohn\u2019s disease were analyzed. During the maintenance treatment, injection intervals were shortened from 12 weeks to 8 weeks in 4 patients who exhibited a loss of response. Ustekinumab trough concentrations were measured using 2 commercial ELISA kits, kit A and kit B.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median trough concentrations measured with kits A and B were 0.26 and 0.38 mcg\/mL, respectively. In the case of kit A, low trough concentrations were undetected on many occasions and measured as zero, whereas kit B displayed their relative values even at low concentrations. Poor clinical parameters, elevated erythrocyte sedimentation rate, C-reactive protein, and calprotectin levels were significantly correlated with lower trough concentrations (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). The area under the receiver operating characteristics curve of kit B (0.921) was greater than that of kit A (0.744). The optimal cutoff values for prediction clinical responses were 0.17 and 0.41 mcg\/mL for kit A and kit B, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The trough concentration of ustekinumab measured by the 2 ELISA kits correlated with laboratory results that indicated the activity of Crohn\u2019s disease. Furthermore, kit B detected even minute changes in trough concentrations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000976","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T15:04:49Z","timestamp":1645110289000},"page":"535-542","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn\u2019s Disease"],"prefix":"10.1097","volume":"44","author":[{"given":"Yiyoung","family":"Kwon","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Kyungpook National University Children's Hospital, Kyungpook National University, Daegu, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sil","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yon Ho","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jmb.2010.07.046","article-title":"Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab","volume":"402","author":"Luo","year":"2010","journal-title":"J Mol Biol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's Disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/ibd\/izaa214","article-title":"Body mass index does not impact clinical efficacy of ustekinumab in Crohn's Disease: a post hoc analysis of the IM-UNITI trial","volume":"27","author":"Wong","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","article-title":"Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease","volume":"7","author":"Bortlik","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5009\/gnl16041","article-title":"Clinical use of measuring trough levels and antibodies against infliximab in patients with pediatric inflammatory bowel disease","volume":"11","author":"Choi","year":"2017","journal-title":"Gut Liver"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cgh.2020.02.033","article-title":"Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn's disease likely to achieve endoscopic and biochemical remission","volume":"19","author":"Hanzel","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/jgh.14962","article-title":"Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease","volume":"35","author":"Morita","year":"2020","journal-title":"J Gastroenterol Hepatol."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1093\/ibd\/izy134","article-title":"Therapeutic drug monitoring with ustekinumab and vedolizumab in inflammatory bowel disease","volume":"24","author":"Restellini","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/a-1088-1461","article-title":"Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease\u2014a regional multi-center pilot study","volume":"58","author":"Thomann","year":"2020","journal-title":"Z Gastroenterol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1016\/j.cgh.2019.02.042","article-title":"Concentrations of ustekinumab during induction therapy associate with remission in patients with Crohn's disease","volume":"17","author":"Soufflet","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MIB.0000000000000624","article-title":"Patients with refractory Crohn's disease successfully treated with ustekinumab","volume":"22","author":"Harris","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.crohns.2014.06.005","article-title":"Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease\u2013the McGill experience","volume":"8","author":"Kopylov","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/0016-5085(86)90206-4","article-title":"A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease","volume":"91","author":"Brignola","year":"1986","journal-title":"Gastroenterology"},{"key":"R21-20250603","first-page":"93","article-title":"Laboratory assessment of disease activity in childhood Crohn's disease and ulcerative colitis","volume":"5","author":"Macfarlane","year":"1986","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T21:01:11Z","timestamp":1748984471000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000976","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"2021-09-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}